Search
Research
Safety and Immunogenicity of MF59-Adjuvanted Cell Culture-Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the ElderlyIn adult and elderly participants, the full-dose aH5N1c vaccine formulation was well tolerated and met US and European licensure criteria for pandemic vaccines
Research
Repeated vaccination does not appear to impact upon influenza vaccine effectiveness against hospitalization with confirmed influenzaThese findings reinforce current recommendations for annual influenza vaccination, particularly those at greatest risk of influenza disease.
Research
Repeat pneumococcal polysaccharide vaccine in Indigenous Australian adults is associated with decreased immune responsivenessThese findings highlight the critical need to evaluate the efficacy of future pneumococcal vaccine programs in the Australian Indigenous populations that recommend repeated doses of 23vPPV.
Research
A controlled human infection model of Streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding studyStreptococcus pyogenes is a leading cause of infection-related morbidity and mortality. A reinvigorated vaccine development effort calls for new clinically relevant human S pyogenes experimental infection models to support proof of concept evaluation of candidate vaccines. We describe the initial Controlled Human Infection for Vaccination Against S pyogenes (CHIVAS-M75) study, in which we aimed to identify a dose of emm75 S pyogenes that causes acute pharyngitis in at least 60% of volunteers when applied to the pharynx by swab.
Research
Does a major change to a COVID-19 vaccine program alter vaccine intention? A qualitative investigationOn 8th April 2021, the Australian Technical Advisory Group on Immunisation (ATAGI) made the Pfizer-BioNtech (Comirnaty) vaccine the “preferred” vaccine for adults in Australia aged < 50 years due to a risk of thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca vaccination. We sought to understand whether this impacted COVID-19 vaccine intentions.
Research
Safety and Immunogenicity of Neonatal Pneumococcal Conjugate Vaccination in Papua New Guinean Children: A Randomised Controlled TrialWe conducted an open randomized controlled trial in Papua New Guinea to compare safety, immunogenicity and priming for memory of 7-valent PCV (PCV7) given in...
Research
Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthyNeisseria meningitidis serogroup B is a major cause of invasive meningococcal disease, but a broadly protective vaccine is not currently licensed. A bivalent...
Research
Polymorphisms in key innate immune genes and their effects on measles vaccine responses and vaccine failure in children from MozambiqueDespite an effective vaccine, measles remains a major health problem globally, particularly in developing countries. More than 30% of children show primary...
Research
Continued challenge of rheumatic heart disease: The gap of understanding or the gap of implementation?We still do not have a RF vaccine, although the recent announcement that the Australian and New Zealand governments are jointly sponsoring a program to fast...
Research
A randomized, controlled, phase 1/2 trial of a neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescentsFactor H binding protein (also known as LP2086) is a conserved outer membrane neisserial lipoprotein that has emerged as a strong candidate protein antigen...